Education 教育背景
2013-2017 BS in Economic Statistics (China)
2018-2019 MSc in Statistics with Distinction (United Kingdom)
Professional Experience 职业经历
2019-2021 Statistical programmer (Global Sponsor)
TA: Inflammation & immunology, phase iii (support NDA [US FDA]; FDA-approved) [Topline/CSR]
TA: Oncology, phase i
2021-2021 SAS/JMP data analyst (Health care division)
JMP plug-in development with JSL/SAS for clinical monitoring by customer request
Customer retention to ensure account satisfaction and growth (customer-facing skills)
Training customers without a statistical education background
2021-2023 Biostatistician, biostatistics (Local Sponsor)
TA: Cardiovascular disease; compound level phase i & iii (Lead Statistician; NDA [China]; Approved by China's NMPA); [SAP/Topline/CSR/DSUR/Publication]
TA: Oncology, phase i & iib (Lead Statistician; Granted a breakthrough therapy designation) [Protocol (including sample size calculation)/SAP/Interim CSR/DSUR/Publication]
TA: Ophthalmology; compound level phase i & iii (Lead Statistician) [Protocol (including sample size calculation)/SAP/CSR]
TA: Inflammatory disease; compound level phase i & iii (Lead Statistician) [Protocol (including sample size calculation)/SAP]
2023-now Biostatistician, biostatistics (Global CRO)
TA: Inflammation & immunology, phase iii, phase iii [SAP/Topline/CSR]
TA: Rare disease; compound level phase iii (support NDA [US FDA]) [SAP/Topline/CSR/Statistical Methodology Appendix/ISS SAP/ISE SAP/BIMO/Ad-hoc Analysis]
TA: Respiratory; compound level phase iii (support NDA [US FDA]) [Pooling Analysis CSR/ISE SAP]
TA: Oncology, phase iii (support NDA [US FDA])
* Data cut: 2024-09-01